Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)

Sponsor
Department of Medical Services Ministry of Public Health of Thailand
Study ID
NCT02860858
Phase
PHASE4
Status
Completed

Conditions

  • Symtomatic Macular Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.

Key Dates

Start date
Dec 30, 2016
Status verified
May 2018
Primary completion
Aug 30, 2018
Completion
Dec 31, 2018

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Aflibercept

Primary Outcome Measure

Best corrected visual acuity (BCVA) [ Time Frame: 2 years ]